Tendon injuries are major musculoskeletal disorders. Polydeoxyribonucleotide activates the adenosine receptor subtype A2A, resulting in tissue growth and neogenesis. This experimental study confirms that polydeoxyribonucleotide can improve secretion of various growth factors, promote collagen synthesis, and restore tensile strength of the Achilles tendon in a rat model with Achilles tendon injury. Thirty-six male Sprague-Dawley rats, aged 7 weeks, were divided into two groups, and the Achilles tendon was transected and repaired using the modified Kessler's method. In the experimental group (n ¼ 18), the rats received daily intraperitoneal administration of polydeoxyribonucleotide (8 mg/kg/day for 1, 2, or 4 weeks). The control groups received the same amount of normal saline. The rats were euthanized at 1, 2, and 4 weeks, and tissues from the repair site were harvested. The cross-sectional area of the tendon was significantly increased at 2 and 4 weeks in polydeoxyribonucleotide group (p ¼ 0.008 and p ¼ 0.017, respectively). Moreover, tendons in the polydeoxyribonucleotide group were more resistant to mechanical stress at 2 and 4 weeks (p ¼ 0.041 and p ¼ 0.041, respectively). The staining levels of collagen type I in the experimental group were significantly stronger at 2 and 4 weeks (p ¼ 0.026 and p ¼ 0.009, respectively). Furthermore, higher expression levels of fibroblast growth factor, vascular endothelial growth factor, and transforming growth factor b1 were detected in the experimental group at 4 weeks (p ¼ 0.041, p ¼ 0.026, and p ¼ 0.041, respectively). This study confirms that polydeoxyribonucleotide can improve the tensile strength of the rats' Achilles tendon following injury and repair. ß
Tendon healing is a slow process that takes several months, which eventually restores tendon fiber continuity and mechanical strength. Tendon repair involves a progression through three stages, starting with the inflammatory phase, which is similar to normal wound healing. Erythrocytes, platelets, neutrophils, monocytes, and macrophages migrate to the site of injury, and angiogenic factors are released during this phase. In the proliferative phase, fibroblasts begin to synthesize collagen, proteoglycans, and randomly arranged extracellular matrix, which is composed largely of collagen type III. Finally, in the remodeling and maturation phase, collagen type III fibers are replaced by collagen type I fibers, which establish the restoration of the mechanical strength of the tendon. 1 Tendon healing is accomplished both by intrinsic healing from the tendon itself and by extrinsic peripheral fibroblasts. 1 Intrinsic healing occurs within the tendon through the movement of proliferated cells from the endotenon and epitenon into the site of injury, whereas extrinsic healing is mediated by the in-growth of inflammatory cells, fibroblasts, and extra-tendinous vascular invasion.
Several growth factors have been implicated in the process of tendon repair, including transforming growth factor-b (TGF-b), vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF). 1 TGF-b is a key cytokine in acute inflammation and wound healing, and induces collagen synthesis, leading to an increase in tensile strength. 2, 3 VEGF is critical for neovascularization, which is essential for the maintenance of the vasculature present in the endotenon and epitenon. 1, 4 Additionally, upregulated bFGF stimulates cell migration, angiogenesis, and cell proliferation of the injured tendon. 5 Polydeoxyribonucleotide (PDRN) is formed by deoxyribonucleotide polymers with chain lengths ranging between 50 and 2,000 base pairs, and may also represent the source of purine and pyrimidine deoxynucleosides/deoxyribonucleotides and bases. 6 It is extracted from the sperm of trout bred for human consumption purposes, and the drug agent can be obtained through purification, ensuring a very high percentage (up to 95%) of PDRN without active proteins or peptides. 7 It has been shown previously that PDRN stimulates the binding of adenosine to A2A receptors, which results in an increase in VEGF expression, differentiation, maturation of fibroblasts, and collagen synthesis to accelerate the granulation tissue formation and the repair process in wound healing. [7] [8] [9] [10] Therefore, we hypothesized that PDRN could improve the secretion of various growth factors, promote collagen synthesis, and restore the tensile strength of tendon in a rat Achilles tendon injury model.
MATERIALS AND METHODS

Experimental Animals
Approvals for all the study protocols were obtained from the Animal Review Committee (IACUC at Chung-Ang Univer-sity) and experiments were conducted at the Animal Research Laboratory of Chung-Ang University Hospital. Throughout the experimental procedure, the use and management of the experimental animals were performed in accordance with the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals (NIH Publications). The experimental animals were 36 male Sprague-Dawley rats, aged 7 weeks, weighing 250-300 g. Rats were observed for 7 days in the animal care laboratory to exclude any possibility of underlying diseases before the start of the experiment and then were used for the experiments.
Experimental Methods
Anesthesia was achieved with an intramuscular injection of 10 mg/kg of tiletamine/zolazepam (Zoletil, Virbac Korea, Seoul) and 2 mg/kg of xylazine hydrochloride (Rompun, Bayer Korea, Seoul). Next, the posterior part of the left leg was shaved, disinfected with betadine, and rinsed with 70% alcohol. Animals were placed in a sterile field on a heated surgery table and covered with a sterile surgical drape, leaving only the prepared limbs exposed. After an injection of lidocaine in the predicted incision line on the skin, the tendon was transected with a No. 15 scalpel blade perpendicular to the collagen fibers. Then, the tendon was repaired with 5/0 nylon sutures, according to the modified Kessler method (Fig. 1 ). The wound was closed primarily in a continuous fashion. The experimental procedures were performed for two groups (control and experimental group). Following the surgical procedure, the rats in the experimental group received daily intraperitoneal administration of PDRN (Placentex Integro, Mastelli Srl, Sanremo, Italy) at a dosage of 8 mg/kg/day for 1 (n ¼ 6), 2 (n ¼ 6) or 4 weeks (n ¼ 6). The control groups received the same amount of intraperitoneal injections of normal saline for 1 (n ¼ 6), 2 (n ¼ 6) or 4 weeks (n ¼ 6). The animals were given intramuscular injections of cefazolin (Chong Kun Dang Pharmaceutical Co., Seoul, Korea) following the procedure. To stimulate early functional rehabilitation, the operated legs were left without splint immobilization. No wound dressing was done after the procedure. All rats were allowed to mobilize freely and were fed with standard laboratory food and tap water.
Tissue Sampling
The rats were sacrificed at 1, 2, and 4 weeks with CO 2 gas. Extensive dissection of the adjacent tissue was performed and repair site tissues were harvested from calcaneus to gastrocnemius muscle. Each sample was immersed in 0.9% saline solution and sent to the lab for biomechanical testing, and was then fixed in buffered (pH 7.4) formalin, embedded in paraffin, and sectioned perpendicularly at the tendon midsubstance. The mean þ SD of the cross-sectional area of the laceration site at 1, 2, and 4 weeks. The cross-sectional area of the tendon was 17.70 AE 3.01 mm 2 , 21.24 AE 1.53 mm 2 , and 18.91 AE 2.32 mm 2 in the control group, and 18.47 AE 2.50 mm 2 , 25.50 AE 2.65 mm 2 , and 24.31 AE 3.57 mm 2 in the experimental group at 1, 2, and 4 weeks, respectively. There was a significant difference between the two groups at 2 and 4 weeks ( ÃÃ p < 0.01, Ã p < 0.05, p ¼ 0.008, 0.017, Mann-Whitney U test). In the experimental group, 2 and 4 weeks groups were significantly higher compared with 1 week group ( ## p < 0.01, # p < 0.05, p ¼ 0.002, 0.013, Mann-Whitney U test).
Biomechanical Evaluation
Before testing, digital calipers (CD-20, Digimatic, Mitutoyo Corporation, Japan) were used to measure the cross-sectional area. The exposed tendons were subjected to biomechanical testing with a mechanical testing machine (Instron, 5565A, Illinois Tool Works, Inc., Norwood, MA). The specimens were then transferred to the uniaxial testing system. All the mechanical testing samples preconditioned before uniaxial testing and deformation tracked via grip-to-grip measurements in the machine. The free ends of the tendon were clamped in the screw vise of the machine (Fig. 2) . The machine recorded the amount of deformation (strain) at distinct intervals of tensile loading (tensile stress) with strain rate 0.167 mm/s. The specimens were tested to mechanical failure, and the maximum load applied to each specimen was recorded by a computer for subsequent data analysis. Each tendon response to the same applied strain presents further complexity to the relationship between load and biologic response. The tensile stress was expressed in a unit area (1 N/mm 2 , megapascal) and represents the mechanical stress of the tissue.
Histology and Immunohistochemistry
Tissues fixed in formalin solution were sectioned at a thickness of 4 mm and stained with hematoxylin and eosin (H&E) stain. For immunohistochemical labeling, the sections were placed in a citrate buffer (10% citrate buffer stock in distilled water, pH 6.0) and blocked with 1% horse serum in Tris-buffered saline, pH 6.0, for 3 min. The sections were incubated with primary antibodies overnight (collagen type I: ab6308; Abcam, Cambridge, MA, 1:500; collagen type III: AF5810, III-53, Novus Biologicals, Littleton, CO, 1:500; transforming growth factor [TGF]-b1: 9016, R&D, Minneapolis, MN, 1:500; fibroblast growth factor: ab8880. Abcam, Cambridge, MA, 1:500; vascular endothelial growth factor: ab46154. Abcam, USA, 1:500). Antibody binding was detected using polymeric methods (Ultravision LP detection system, TL-125-HD, Thermo Scientific, Fremont, CA). Detection was performed with appropriate secondary antibodies conjugated with horseradish peroxidase, and labeling was visualized with diaminobenzidine.
Statistical Analyses
Statistical analysis was performed using SigmaPlot (ver. 12.0, Systat Software, Inc., Point Richmond, CA). Data are expressed as the mean AE SD. For convenience of statistical analysis, each immunohistochemical evaluation was scored on a point-based system (0% as 0, 0% to 25% as 1þ, 25% to 50% as 2þ, and 50% and above as 3þ; 0 point for þ-, 1 point for 1þ, 2 points for 2þ, and 3 points for 3þ). Statistical analyses were performed using the Mann-Whitney U test for comparing two groups. We used the Mann-Whitney U test for comparing mechanical properties and cross-sectional area too. The comparisons were done in a double-blinded fashion. A p-value of <0.05 was considered to indicate a significant difference.
RESULTS
Biomechanical Evaluation
No significant difference in the body weight was observed between each group at the different times of the experiment. Results are expressed as the mean AE the standard deviation of the mean. The cross-sectional area of the tendon was 18.47 AE 2.50 mm 2 , 25.50 AE 2.65 mm 2 , and 24.31 AE 3.57 mm 2 in the experimental group, and 17.70 AE 3.01 mm 2 , 21.24 AE 1.53 mm 2 , and 18.91 AE 2.32 mm 2 in the control group at 1, 2, and 4 weeks, respectively. There was no significant difference in the cross-sectional areas of the laceration sites between the two groups at 1 week (p ¼ 0.620). However, the area was significantly increased at 2 and 4 weeks in PDRN group (p ¼ 0.008, 0.017) ( Fig. 3) . Furthermore, the cross-sectional area was significantly higher at 2 and 4 weeks in the experimental groups compared with 1 week group (p ¼ 0.002, 0.013). On the other hand, there were no differences between control tendons across time points. A typical tensile stressstrain curve and load-displacement curve at each tendon are shown in Figures 4 and 5 . Tendons in the PDRN group were more resistant to mechanical stress at 2 and 4 weeks compared with those in the control group. We calculated stress-strain curve area (area under the curve, J/m 3 ) to compare the stored energy in both groups at each time point ( Fig. 6 ). No statistically significant difference was detected at 1 week (stored energy at 1 week for the experimental group, 2.82 AE 0.68 J/m 3 ; and the control group, 2.63 AE 0.68 J/ m 3 , p ¼ 0.699) However, the stored energy was significantly higher at 2 and 4 weeks in the experimental group (at 2 weeks for the experimental group, 4.66 AE 1.25 J/m 3 ; and the control group, 3.71 AE 0.32 J/ m 3 , p ¼ 0.041: at 4 weeks for the experimental group, 7.47 AE 1.97 J/m 3 ; and the control group, 5.19 AE 1.65 J/ m 3 , p ¼ 0.041). There were significant differences in stored energy between control groups across timepoints. (1 week group versus 2 weeks group, p ¼ 0.004; 1 week group versus 4 weeks group, p ¼ 0.004; 2 weeks group versus 4 weeks group, p ¼ 0.041). These significances were also observed in the experimental groups.
(1 week group versus 2 weeks group, p ¼ 0.004; 1 week group versus 4 weeks group, p ¼ 0.002; 2 weeks group versus 4 weeks group, p ¼ 0.015) There was no significant difference in the maximal tensile stress and load of the tendons between the two groups (Table S1 ). However, there were significant differences in each group across time-points. These significant differences Figure 6 . Comparison of the stored energy between the experimental and control group. There was no significant difference at 1 week (p ¼ 0.699). However, the stored energy was significantly higher at 2 and 4 weeks in the experimental group compare to control group ( Ã p < 0.05, Mann-Whitney U test). Moreover, there were significant differences in the both group at 2 and 4 weeks compare to 1 week group ( ## p < 0.01, Mann-Whitney U test). (Table S2) .
Histology and Immunohistochemical Evaluation
The hematoxylin and eosin (H&E) stained sections of the PDRN group at 2 and 4 weeks showed dense collagen fibers and fibroblast arrangement with an organized pattern. However, no obvious difference in histology was observed between the two groups at 1 week (Fig. 7) . Immunohistochemistry was used for semi-quantitative assessment. For convenience of statistical analysis, the intensity of the immunohistochemical staining of collagen type I, collagen type III, FGF, VEGF, and TGF-b1 was scored on a point-based Figure 8 . Representative histologic sections with Anti-collagen type I immunohistochemical stain (Â200). The levels of staining for collagen type I in the experimental group were significantly stronger in the PDRN-treated group than that in the control group at 2 and 4 weeks. Figure 9 . Representative histologic sections with Anti-fibroblast growth factor immunohistochemical stain (Â200). The levels of staining for FGF in the experimental group were significantly stronger in the PDRN-treated group than that in the control group at 4 weeks.
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KANG ET AL. system (Table S3 ). The levels of staining of collagen type I in the experimental group were significantly stronger than those in the control group at 2 and 4 weeks (p ¼ 0.026, 0.009) ( Fig. 8 , Table S3 ). Furthermore, higher expression of FGF, VEGF, and TGF-b1 was detected in the experimental group at 4 weeks compared with that in the control group (p ¼ 0.041, 0.026, 0.041) ( Figs. 9-11 , Table S3 ). All immunohistochemical stain degrees were significantly increased in the tendons of the PDRN group at 4 weeks. In addition to this, there were significant differences in collagen type I and III expression between control groups across time-points in 2 and 4 weeks groups compared with 1 week group. These significances were also observed in the Figure 10 . Representative histologic sections with Anti-vascular endothelial growth factor immunohistochemical stain (Â200). The levels of staining for VEGF in the experimental group were significantly stronger in the PDRN-treated group than that in the control group at 4 weeks. Figure 11 . Representative histologic sections with Anti-transforming growth factor beta 1 immunohistochemical stain (Â200). The levels of staining for TGF-b1 in the experimental group were significantly stronger in the PDRN-treated group than that in the control group at 4 weeks.
POLYDEOXYRIBONUCLEOTIDE IMPROVES ACHILLES TENDON INJURY
experimental groups (Table S4 ). Furthermore, FGF and VEGF expressions in the experimental groups were significantly higher across time-points (Table S4) . On the other hand, there were no significant differences in TGF-b1 expressions except comparison 1 week versus 4 weeks in experimental group.
DISCUSSION
Tendon injuries such as laceration, rupture, or inflammation, cause severe issues with mobility and can have a major impact on work, recreational activities, and daily needs. The restoration of mechanical strength is the most important factor in tendon repair and would enable early mobilization, and thus improve the range of motion of the joint. Collagen type I synthesis is the most crucial step in the determination of the tensile strength, whereas collagen type III is the initiator of the tendon-healing process, supplied by the fibroblasts and the tenocytes. 10 The techniques that have been developed for the repair of tendon injury include surgical treatment, biological treatment, physical therapy, and biomaterials of adjuvant therapy. 11 Because surgical treatment and post-treatment regimens are already refined, biological approaches, such as the application of growth factors or agents, were attempted by numerous studies. Exogenous administration of VEGF and TGF-b1 improved tensile strength in the early healing process of rat Achilles tendon, 12, 13 and a transferred PDGF gene increased the expression of PDGF and collagen type I in vitro. 14 IGF-1 and FGF also stimulated cell proliferation and accelerated the early stage of tendon healing in a rat model. 15, 16 Because tendon healing is not triggered by a single growth factor, but requires the interplay of multiple factors, in some studies, autologous conditioned serum preparation, adipose-derived stem cells, or platelet-rich plasma that contains a mixture of growth factors, are applied in animal Achilles tendon models, and they have been shown to enhance tendon healing. 2, [17] [18] [19] It is well known that nucleotides, nucleosides, and purine/pyrimidine bases stimulate cellular proliferation. 8, 9, [20] [21] [22] [23] They enhance nucleic acid synthesis through the salvage pathways and/or binding to the purinergic receptors. Purine receptors are divided into two subclasses: P1, which responds to nucleosides, and P2, which responds to nucleotides. P1 receptors are subdivided into A1, A2A/2B, and A3 subtypes, while P2 receptors include a number of subtypes designated P2X, Y, U, Z.20, 2424 Among the purinergic receptors, the activation of the adenosine A2A receptor induces G protein activation, leading to cyclic AMP (cAMP) signaling events, activation of protein kinase A (PKA), and cell proliferation. 20 The A2A receptor stimulates not only the secretion of VEGF 9 and TGFb, 25 but the proliferation of fibroblasts, 23 osteoblasts, 21 and endothelial cells, 9 as well as collagen synthesis. 8, 22 Moreover, it has a synergistic effect with other growth factors, 26, 27 and accelerates angiogenesis and wound healing. 22 PDRN is the active fraction of a preparation used in therapy as a tissue repair and stimulating agent, and acts on the adenosine A2A receptor. Although the molecular mechanism behind how PDRN activates the A2A receptor and cell proliferation is still far from being fully understood, it has successfully stimulated angiogenesis, enhanced cell proliferation, and promoted wound healing in some experimental pathologies, including thermal injury, 28 skin graft donor sites, 29 wounds in diabetic mice, 7 peripheral occlusive disease, 3 and random pattern skin flaps. 30 These observations support the hypothesis that PDRN enhances tendon healing in a rat model.
In the present study, the PDRN-treated group showed an increased cross-sectional area and stored energy which was evaluated by the area under the curve. Also, the significant differences of maximal tensile stress and load values in experimental group across time points are more prominent than the control group (Table S2) . These finding are supported by semi-quantitative immunohistochemical analysis with collagen type I, FGF, VEGF, and TGF-b1. The expression of collagen type I was increased in the PDRN-treated group at 2 and 4 weeks, which was consistent with our findings on biomechanical properties. All of these findings are in agreement with the reports that the adenosine A2A receptor stimulates FGF, VEGF, and TGF-b1 secretion and collagen type I synthesis. 8, 9, 22, 25, 31 The improvement of tensile stress and stored energy in the PDRN-treated tendons indicated an increase in collagen synthesis, specifically type I. Based on a previous study of the elevation of TGF-b1 mRNA in the injured tendon, 3 PDRN could mediate the expression of TGF-b1, which plays an important role in the healing process of tendon injury through both intrinsic and extrinsic mechanisms by directing the migration of fibroblasts and the secretion of ECM proteins. It is closely related to collagen type I synthesis, which is important in the restoration of tensile strength. 1, 12, 18 The role of collagen type III has not yet been thoroughly understood. Previously, bFGF was shown to increase collagen type III expression in the early stage of tendon healing in a rat patellar tendon injury model, 15 but TGF-b1 was shown to decrease procollagen type III mRNA expression at 2 week in a rat Achilles tendon model. 12 Furthermore, an increased amount of collagen type III in the fibers would tend to reduce their tensile strength. 18 Based on our analysis of collagen types in the tendon, the expression of collagen type I was increased to a great degree in the PDRN-treated group at 2 and 4 weeks, and the expression of collagen type III showed no significant differences between the two groups. With improved collagen synthesis, which is apparent from the significantly greater tendon thickness at 2 and 4 weeks, tensile stress was also significantly increased at 2 and 4 weeks (p ¼ 0.041). Although not enough to show statistical significance, the Table S3 shows that the scores related to growth factors are generally higher in the experimental group than in the control group. Moreover, in the Table S4 , all the growth factors in experimental group tend to increase across time-points. These significant differences are more prominent in the experimental group than the control group.
The limitations of the present study are the sexual variation (lack of female animals), the small number of experimental animals, the short-term follow-up time, and the lack of quantitative evaluation. The long-term effects of PDRN on tendon healing should also be investigated. Nevertheless, our results support the hypothesis that intraperitoneally injected PDRN can improve tensile strength in rat Achilles tendon healing. Further studies should be conducted to establish the mechanism of PDRN in different phases during the tendon healing process and to prove safety for application in humans and to establish the optimal doses that should be used.
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